👁️🗨️ Lupin Signs LATAM Deal for Biosimilar Ranibizumab — Will This Eye Drug Open Billion-Dollar Latin America for India’s Pharma Giant?

📌 At a Glance
Lupin (CMP ₹1,988.20, NSE: LUPIN) has just inked a license and supply agreement with SteinCares, a LATAM-based specialty healthcare player, to commercialize its biosimilar of Ranibizumab (think: cheaper Lucentis) in Latin America — excluding Mexico and Argentina.

It’s a no-brainer play in ophthalmology, where the therapy costs have been insane and access, limited. Now Lupin gets to ride on SteinCares’ regional muscle while keeping the manufacturing game in-house.

💉 What’s the Drug?

Ranibizumab is a biosimilar of Lucentis, used to treat:

• Wet Age-Related Macular Degeneration (wAMD)
• Diabetic Macular Edema (DME)
• Diabetic Retinopathy (DR)
• Retinal Vein Occlusion (RVO)
• Myopic CNV (mCNV)

This is a high-cost, high-demand molecule, and with populations aging across Latin America, ophthalmic therapies are booming.

📈 Deal Structure

Lupin doesn’t have to build boots on the ground — it gets LATAM exposure without LATAM headaches.

🧠 EduInvesting Take

“Lupin just got access to 500 million eyeballs — without blinking.”

This is textbook smart capital-light expansion:

• Lupin does what it does best: manufacture with global regulatory standards
• SteinCares does what it does best: run regional approvals and market access like a Latin American pro

💡This deal = zero SG&A costs for Lupin and a net-margin play via volume-based biosimilars.

🌎 Why Latin America?

Latin America is five years behind the West in biosimilar adoption — which is perfect timing for